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A B S T R A C T
The calcitonin receptor-like receptor (CLR) acts as a receptor for the calcitonin gene-related peptide
(CGRP) but in order to recognize CGRP, it must form a complex with an accessory protein, receptor
activity modifying protein 1 (RAMP1). Identifying the protein/protein and protein/ligand interfaces in
this unusual complex would aid drug design. The role of the extreme N-terminus of CLR (Glu23-Ala60)
was examined by an alanine scan and the results were interpreted with the help of a molecular model.
The potency of CGRP at stimulating cAMP production was reduced at Leu41Ala, Gln45Ala, Cys48Ala and
Tyr49Ala; furthermore, CGRP-induced receptor internalization at all of these receptors was also
impaired. Ile32Ala, Gly35Ala and Thr37Ala all increased CGRP potency. CGRP speciﬁc binding was
abolished at Leu41Ala, Ala44Leu, Cys48Ala and Tyr49Ala. There was signiﬁcant impairment of cell
surface expression of Gln45Ala, Cys48Ala and Tyr49Ala. Cys48 takes part in a highly conserved disulﬁde
bond and is probably needed for correct folding of CLR. The model suggests that Gln45 and Tyr49
mediate their effects by interacting with RAMP1 whereas Leu41 and Ala44 are likely to be involved in
binding CGRP. Ile32, Gly35 and Thr37 form a separate cluster of residues which modulate CGRP binding.
The results from this study may be applicable to other family B GPCRs which can associate with RAMPs.
 2009 Elsevier Inc.
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d. Introduction
Calcitonin gene-related peptide (CGRP) is an abundant 37
mino acid peptide found throughout the sensory nervous system.
t is an extremely potent vasodilator and it is an important
ediator of neurogenic inﬂammation. The CGRP receptor is
nusual as its subunits include a family B G-protein coupled
eceptor (GPCR) called the calcitonin receptor-like receptor (CLR)
nd a receptor activity modifying protein (RAMP1) as well as an
dditional peripheral membrane protein, receptor component
rotein [8]. Interaction of CLR with the homologous proteins
AMP2 and RAMP3 gives receptors for the peptide adrenomedullin
although the RAMP3-containing complex retains reasonable
fﬁnity for CGRP) [19]. Recent work suggests that the CGRP
eceptor is formed by the association of a RAMP1 monomer with a
bbreviations: CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-likeeceptor; ECD, extracellular domain; GPCR, G-protein coupled receptor; HA,
emagglutinin; pEC50, –log(EC50); PBS, phosphate buffered saline; RAMP, receptor
ctivity modifying protein; WT, wild-type.
* Corresponding author. Tel.: +44 121 204 3997; fax: +44 121 359 5142.
E-mail addresses: Barwellj@aston.ac.uk (J. Barwell), philipsaxon@gmail.com
P.S. Miller), D.Donnelly@leeds.ac.uk (D. Donnelly), D.R.Poyner@aston.ac.uk
(D.R. Poyner).
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Open access under CC BY-NC-ND license. dimer of CLR [12]. Understanding this receptor on a mechanistic
level presents considerable challenges. However this is not only
important in understanding the intrinsic properties of the CGRP
receptor, but may provide insight on how a number of other family
B GPCRs interact with RAMPs, most notably the calcitonin receptor
which generates amylin receptors [4,21].
A general model is now emerging of ligand binding to family B
GPCRs in which the C-termini of the ligands lie alongside the
extreme N-termini of the corresponding receptors [22,25]. It is
tempting to assume that CGRP adopts a similar mode of binding to
its receptor. However, the requirement for RAMP1 complicates
matters. The extreme N-terminus of CLR is an important site for
both CGRP [2] and RAMP association [14], so it is plausible that it
could interact directly with CGRP and RAMP1. However, the
functional role of individual amino acids in this region has not been
examined.
To further investigate the role of the extreme N-terminus of
CLR, we report the results of an alanine scan on residues 23–60 of
this protein, representing the ﬁrst 38 residues of the receptor after
removal of the signal peptide. Two clusters of residues are shown
to be important for CGRP action. At the end of the epitope,
modeling suggests Gln45 and Tyr49 are chieﬂy involved in
interacting with RAMP1, whereas Leu41 and Ala45 facilitate CGRP
J. Barwell et al. / Peptides 31 (2010) 170–176 171binding. In the middle of the epitope, Ile32, Gly35 and Thr37 also
inﬂuence CGRP binding. It is possible that this model can be
extended to amylin and calcitonin receptors.
2. Methods
2.1. Materials
Human aCGRP was from Calbiochem (Beeston, Nottingham,
UK). 125I-iodo8histidyl-human aCGRP was from PerkinElmer Life
and Analytical Sciences (Waltham, MA). [8-3H] Adenosine 30, 50,
cyclic phosphate, NH4 salt was from Amersham Biosciences
(Chalfont, UK). Chemicals were from Sigma–Aldrich UK.
2.2. Expression constructs and mutagenesis
Human CLRwith an N-terminal hemagglutinin (HA) epitope tag
and human RAMP1 with an N-terminal myc epitope tag were
mutated using the Quik Change II site-directed mutagenesis kit
(Stratagene, Cambridge, UK), as described previously [6].
2.3. Cell culture and transfection
Cos-7 cells were cultured and transfected with polyethylenei-
mine as described previously [28].
2.4. Radioligand binding
Conﬂuent cells from ﬁve 160-cm2 Petri dishes (pre-coated with
poly-D-lysine), were washed with phosphate buffered saline (PBS),
followed by the addition of 15 ml of ice-cold sterile double distilled
water to induce cell lysis. Following 5 min incubation on ice, the
ruptured cells were washed with ice-cold PBS before being scraped
from the plates and pelleted in a bench-top centrifuge (13,000  g
for 30 min). The membrane pellet was resuspended in 1 ml binding
buffer (25 mM HEPES pH 7.4, 2.5 mM CaCl2, 1 mM MgCl2, 50 mg/L
bacitracin) and forced through a 23G needle. 0.1 ml aliquots were
snap-frozen in liquid nitrogen and stored at 70 8C. Membranes
were slowly thawed on ice before diluting to a concentration that
gave total radioligand binding of <10% total counts added. In a
reaction volume of 200ml, 75 pM (60,000 cpm) 125I-CGRP with or
without 1mMunlabelled CGRP andmembraneswere combined, all
diluted in binding buffer. Assays were carried out for 1 h in
MultiScreen 96-well ﬁltration plates (glass ﬁbre ﬁlters, 0.65mm
poresize,Millipore, Bedford,MA)pre-soaked in1%non-fatmilk/PBS.
After the incubation, membrane-associated radioligand was har-
vested by transferring the assay mixture to the ﬁltration plate
housed in a vacuummanifold. The wells of the ﬁltration plate were
washed three times with 0.2 ml PBS before harvesting the ﬁlter
discs. Filter-bound radioactivity was measured in a gamma counter
(RiaStar 5405 counter; PerkinElmer Life and Analytical Sciences,
Waltham,MA). Non-speciﬁc bindingwas1% of total counts added.
2.5. Assay of cAMP production
48-Well plates were transiently transfected with WT receptor
(HA CLR/myc RAMP1) alongside a mutant receptor in every
experiment, to take account of day-to-day differences in transfec-
tion and coupling efﬁciencies. Stimulation with agonists and assay
of cAMP was by a radioreceptor assay as described elsewhere [28].
2.6. Analysis of cell surface expression of mutants by ELISA and
agonist dependent internalization
24-Well plates were transiently transfected withWT receptor a
mutant receptor in every experiment. A negative control of mycRAMP1/empty pcDNA3.1() was used. The ELISA was carried out
as described previously to measure both cell surface and total
expression of CLR [28]. Cell surface expression data was normal-
ized to make mean WT expression 100% and the mean myc
RAMP1/empty pcDNA3.1() vector as 0%. Receptor internalization
was measured after 1 h treatment with 100 nM human aCGRP at
37 8C by ELISA as described previously [7].
2.7. Molecular modeling
A comparative structure of the extracellular domain (ECD) of
CLR, from residues 23–134 was generated using Modeller9v3 [9]
based on the gastric inhibitory peptide receptor- and parathyroid
hormone type 1 receptor-ECDs [22,25]. This gave 500 models
which were ranked by Modeller9v3 energy objective function. The
stereochemical quality of the top 20 structures was assessed by
PROCHECKv3.5.4 [17] to select the bestmodel. The program LOOPY
[5] was used to build 2000 initial loop conformations for loops 2
and 3 and 4000 conformations for loop 1. LOOPYwas used to attach
the loops to the protein by a random tweak method and then to
perform a fast energy minimization on torsional space to allow the
program SCAP to predict and build the protein side-chains. Initial
loop conformations were ranked by DFIRE 2.0 [29] statistical
energy function. The top conformers underwent a physical-based
scoring method [24] using AMBER99 in the presence of General-
ised Born solvation model [26] implemented in the TINKER
program package (http://dasher.wustl.edu/tinker/). Minimized
fragments were subsequently ranked by total energy potential
by the program ANALYZE in TINKER. A conformation from the top
10 structures was selected based on the architecture of the loops in
other family B GPCR ECDs and the total energy potential score of
the loop conformer. The H++ web server (http://biophysics.cs.v-
t.edu/H++/) was used to calculate the protonation states of
titratable sites in CLR ECD (external dielectric constant = 80,
internal dielectric constant = 6, salinity = 0.15 M, pH = 7.2). Gro-
macs v4.0 [13] was used for the reﬁnement of the CLR ECD.
The CLR ECD was docked against itself with GRAMMv1.03 [1]
using the generic low resolution settings to produce 1000
complexes. These were ranked based on residue level pair
potentials scoring, using the 3D-Dock suite [20]. The dimer
interface was reﬁned using the MULTIDOCK program from the 3D-
Dock suite. RAMP1 ECD was docked onto the CLR ECD complex
using the strategy described above. The resulting trimer was
reﬁned with Gromacs v4.0, utilizing the OPLS-AA/L force ﬁeld
parameters to perform a deepest descent energy minimization in
the presence of an explicit SPC/E water model with neutralizing
Na+ ions.
2.8. Data analysis
For the radioligand binding assays, speciﬁc binding of mutants
was compared to WT by Tukey’s test following a one-way ANOVA.
For cAMP measurements, Prism 4 (Graphpad Software Inc., San
Diego, CA)was used to generate sigmoidal concentration–response
curves. A two-tailed unpaired t-test was used to compare WT and
mutant pEC50 values, basal and maximum cAMP production. For
ELISA-based analysis of total receptor expression, cell surface
expression and internalization, a Mann–Whitney test was used to
compare WT with mutants.
3. Results
3.1. Stimulation of cAMP production
Each mutant was challenged with human aCGRP and cAMP
production was measured. Ile41Ala, Gln45Ala, Cys48Ala and
Fig. 1. CGRP-stimulated cAMP responses of themutated receptors where there is a decrease in potency. (a) I41A, (b) Q45A, (c) C48A and (d) Y49A. Cos-7 cells were transfected
with WT/RAMP1 or mutant/RAMP1 and assayed for CGRP-stimulated cAMP production. WT type receptors; open squares. Mutant receptors; as indicated. Data are
representative of three to ﬁve similar experiments.
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mutant Ala44Leu showed an 8-fold decrease in potency, although
this did not reach statistical signiﬁcance. Ile32Ala, Gly35Ala and
Thr37Ala showed an approximate 10-fold increase in potency
(Fig. 2, Table 1). There were no signiﬁcant potency changes at any
other mutant. Glu39Ala showed an increased maximum response
(80.9  8.0% increase above WT) and Lys51Ala showed increased
constitutive activity (30.2  7.0% increase in basal cAMP production
compared to WT) (Fig. 2). Neither of these parameters were
signiﬁcantly changed for any other mutant (Supplementary Table 1).
3.2. Receptor expression and radioligand binding
A change in potency could be either because the mutants no
longer boundCGRPwith high afﬁnity, or because the receptorswere
not at the cell surface. Accordingly, cell surface expression of
receptors was measured (Table 2). Large reductions were seen for
Gln45Ala, Cys48Ala and Tyr49Ala with small reductions forTable 1
Ability of mutant receptors to stimulate cAMP production.
Mutant N pEC50 WT pEC50 mutant
E23A 4 8.980.32 9.180.37
L24A 4 9.090.35 9.390.42
E25A 6 10.080.40 9.720.39
E26A 5 9.330.57 9.330.21
S27A 4 9.260.14 9.510.34
P28A 4 9.110.33 9.900.37
E29A 4 9.410.14 9.260.20
D30A 4 9.660.29 9.680.41
S31A 7 9.110.31 9.000.37
I32A 4 8.950.14 9.630.13*
Q33A 3 9.280.22 9.040.03
L34A 7 9.550.30 9.510.23
G35A 6 9.070.12 10.090.24**
V36A 4 9.270.18 9.900.30
T37A 5 9.150.17 10.080.23*
R38A 5 9.170.15 9.320.35
N39A 4 9.240.34 9.550.42
K40A 4 9.610.15 10.010.25
I41A 7 10.020.34 9.220.096*
Values are means s.e.m. *, **, p> 0.05 and 0.01 compared to WT, Student’s, t-test.Thr43Ala and Ala44Leu. Efﬁcient expression of CLR requires its
association with RAMP1 for transport to the cell surface [19]. Total
CLRproduction asmeasured for thesemutants byawhole-cell ELISA
was only signiﬁcantly reduced for Ala44Leu (81.7  6.5% ofWT) and
Tyr49Ala (77.6  3.8% of WT). This suggests that all these mutants are
synthesized with reasonable efﬁciency so the reduction in cell surface
expression is because of defective trafﬁcking or insertion into the
membrane. Whilst nine mutants showed a signiﬁcant increase in cell
surface expression, only for Arg38Ala and Tyr46Ala was this increase
greater than 50% of the WT; these were also the only two mutants to
show a greater than 50% increase in total cell expression (158.8  7.6%
and 196.6 30.0% of WT respectively, Table 3).
3.3. Radioligand binding
For four mutants, Ile41Ala, Ala44Leu, Cys48Ala and Tyr49Ala,
high afﬁnity CGRP bindingwas abolished (Table 2), consistentwith
the reduced potency and/or expression shown by these receptors.Mutant N pEC50 WT pEC50 mutant
M42A 6 9.81 0.26 9.860.10
T43A 3 9.77 0.41 9.740.37
A44L 5 9.32 0.20 8.410.45
Q45A 3 9.11 0.08 8.100.18**
Y46A 4 9.17 0.19 9.120.44
E47A 5 9.57 0.21 9.400.32
C48A 7 10.09 0.23 8.770.38**
Y49A 6 9.71 0.19 8.760.18**
Q50A 5 9.49 0.10 9.610.49
K51A 4 9.45 0.37 9.660.25
I52A 6 9.79 0.24 9.860.29
M53A 5 9.72 0.30 10.200.24
Q54A 4 9.38 0.15 9.600.33
D55A 5 9.33 0.30 9.760.13
P56A 3 9.74 0.14 9.210.18
I57A 3 9.23 0.27 9.270.33
Q58A 6 10.12 0.36 10.280.37
Q59A 5 9.68 0.26 9.700.32
A60L 6 9.65 0.44 9.560.43
Table 2
Cell surface expression and binding properties of mutant receptors.
Mutant % Expression % Binding Mutant % Expression % Binding
E23A 108.75.1 81.74.0 M42A 83.26.3 97.212.0
L24A 111.19.2 101.63.5 T43A 83.65.3* 87.612.3
E25A 143.016.4* 90.612.5 A44L 82.76.0* 4.31.6*
E26A 123.78.6 71.910 Q45A 66.63.3*** 61.43.7
S27A 117.17.5 116.422.2 Y46A 167.08.6*** 71.416.7
P28A 95.99.9 90.214 E47A 81.74.7 ** 9010.7
E29A 108.69.7 90.50.8 C48A 45.43.9*** 2.71.2*
D30A 123.46.3** 74.15 Y49A 33.85.6*** 5.53.1*
S31A 111.49.7 98.62.4 Q50A 98.59.4 93.52.5
I32A 114.39.9 114.713.7 K51A 82.08.4 85.96.7
Q33A 141.08.3*** 59.214.2 I52A 123.95.8* 86.21.9
L34A 129.414.6 10314.2 M53A 109.65.1 95.86.7
G35A 147.69.2** 1038.4 Q54A 106.59.3 103.115.8
V36A 116.19.3* 87.86 D55A 100.57.9 86.710.4
T37A 108.58.6 88.38.1 P56A 131.17.0** 83.38.8
R38A 161.79.0*** 89.08.6 I57A 105.49.9 102.14.3
N39A 147.610.0** 94.913.5 Q58A 88.010.6 78.87.9
K40A 83.94.0 91.19.0 Q59A 102.97.9 82.16.6
I41A 133.68.7 2.02.7 A60L 79.47.1 104.96
Expression shows cell surface expression of HA-tagged receptors, 3–6 experiments;WT expression=100%. *, **, ***, p>0.05, 0.01 and 0.001 compared toWT,Mann–Whitney.
Binding shows % speciﬁc binding of 125I-CGRP; WT receptor binding=100%, n=3. Values are means s.e.m. *, **, ***, p> 0.05, 0.01 and 0.001 compared to WT, Student’s t-test.
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afﬁnity binding (Kd < 10 nM), whereas a functional assay will
continue to respond to much weaker associations; hence the
apparent discrepancy that Ile41Ala and Cys48Ala give a cAMP
response in the absence of detectable binding of radioligand There
was a reduction in the binding seen with Gln45Ala, although this
did not reach signiﬁcance.
3.4. Receptor internalization
Following an hour pre-treatment with 100 nM CGRP, the cell
surface expression of the WT receptor was typically reduced by
about 60% (Table 4). Fourteenmutants showed changes in receptor
internalization. Large effects were seen with Ile41Ala, Ala44Leu,
Gln45Ala, Cys48Ala and Tyr49Ala, where it was either greatlyFig. 2. CGRP-stimulated cAMP response of themutated receptorswhere there is either an
Cos-7 cells were transfected withWT/RAMP1 or mutant/RAMP1 and assayed for CGRP-s
indicated. Data are representative of three to ﬁve similar experiments.impaired or totally abolished. These residues show impaired cAMP
responsiveness, conﬁrming their importance.
3.5. Molecular modeling
To assist with the interpretation of the mutagenesis, a
speculative model has been produced of the CLR/RAMP1 complex
(Fig. 3). It is proposed that the CGRP receptor ECD is an
asymmetrical trimer, consistent with recent data [12].
An initial homology model of the CLR ECD was built based on
the gastric inhibitory peptide receptor- and parathyroid hormone
type 1 receptor-ECDs [22,25], as described in themethods. The CLR
ECD contains three loop regions, loop1 (Asp55-Arg67), loop2
(Asn76-Gly81) and loop3 (Pro89-Ser98). These weremodeledwith
the program LOOPY [5]. A conformation from the top 10 structuresincrease in potency or constitutive activity. (a) I32A, (b) G35A, (c) T37A and (d) K51A.
timulated cAMP production. WT type receptors; open squares. Mutant receptors; as
Table 3
Total expression of mutated receptors.
Mutant N Total expression
(% of WT)
Mutant N Total expression
(% of WT)
E23A 9 91.43.4 I41A 9 100.16.7
E25A 9 88.71.7 T43A 15 116.09.4
E47A 9 99.52.0 A44L 9 81.76.5*
D30A 12 141.511.0* Q45A 14 109.113.8
I32A 9 138.17.6*** Y46A 15 196.630.0***
Q33A 9 135.011.9 C48A 9 91.53.08
G35A 12 126.75.3** Y49A 9 77.63.8*
T37A 9 112.99.3 I52A 9 176.113.3*
R38A 12 158.87.6*** P56A 9 111.614.9
N39A 12 130.67.1**
Total cellular expression of mutants that showed a signiﬁcant change in cell surface
expression were measured by a whole-cell ELISA. Values are expressed as % WT
expression and are means s.e.m. **p>0.05 and 0.01 compared to WT, Mann–
Whitney test.
Table 4
Internalization of receptors.
Mutant N % Internalization
WT Mutant
E23A 14 60.875.94 61.155.45
L24A 14 57.476.38 63.813.77
E25A 12 57.653.92 57.424.45
E26A 12 71.105.76 71.663.79
S27A 12 58.406.98 53.367.22
P28A 14 62.655.48 58.272.85
E29A 21 63.405.64 60.342.86
D30A 9 65.402.68 57.555.80*
S31A 18 59.865.98 64.015.71
I32A 15 64.965.86 46.424.43*
Q33A 15 63.924.20 52.424.14*
L34A 11 54.844.78 48.114.84
G35A 20 62.515.34 61.183.24
V36A 16 55.776.11 44.868.79
T37A 12 61.895.12 54.015.50
R38A 15 54.545.99 33.795.02*
N39A 13 54.443.13 62.205.60
K40A 9 67.165.22 64.614.02
I41A 9 50.066.03 16.929.94***
The internalization of the WT receptor (as assessed by cell surface ELISA) was compa
normalized against the cell surface expression prior to addition of CGRP and aremeans
0.001, Mann–Whitney.
Fig. 3.Model of the CLR: RAMP1 complex. (a) RAMP1 and CLR ECD-A interface residues in
orientations of the subunits of CGRP receptor ECD; the proposed interaction of K51 wi
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B GPCR ECDs and the total energy potential score of the loop
conformer, as described in the methods.
The CLR ECD was docked against itself to produce 1000
complexes. The top 10 complexes were visually inspected and
assessed based on molecule orientation. The C-terminus region of
both the CLR ECDs (CLR ECD-A and CLR ECD-B, respectively) are
predicted to face the same direction, as would be expected in vivo,
as this region in bothmolecules would be expected to be facing the
lipid bilayer. A complex that satisﬁed these requirements was
selected. The dimer interface was reﬁned using the MULTIDOCK
program from the 3D-Dock suite as described in the methods.
The model suggests that the two CLR ECDs dock together to
produce a roughly symmetrical complex. The interface between
them is located in loop3 between Pro89 and Ser98. The
corresponding loop in the mouse corticotrophin receptor ECD is
predicted to be relatively stable as evidenced by very broad cross-Mutant N % Internalization
WT Mutant
M42A 15 52.156.68 60.325.58
T43A 9 66.035.30 69.753.56**
A44L 12 71.162.30 51.673.59
Q45A 9 54.842.69 27.457.51**
Y46A 9 89.192.05 56.833.73***
E47A 9 68.722.89 61.442.85
C48A 15 57.043.36 14.654.2***
Y49A 18 49.804.81 0.009.34***
Q50A 15 68.583.42 65.793.06
K51A 9 73.142.87 76.483.57
I52A 14 75.734.89 51.414.06***
M53A 9 68.284.54 65.223.41
Q54A 18 65.976.18 63.034.29
D55A 12 72.801.96 65.322.74
P56A 15 72.162.78 56.222.71***
I57A 15 68.286.03 59.617.04
Q58A 9 69.324.83 75.503.29
Q59A 9 49.423.45 59.903.33
A60L 9 55.803.23 57.094.14
red with that of each mutant in paired experiments. Values are % internalization,
s.e.m, n =9–18 derived from 3 to 6 independent experiments. *, **, ***, p> 0.05, 0.01 and
italics are on RAMP1, those in normal type are on CLR. (b) Side view of the predicted
th D96 is also shown for one of the CLR pairs.
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plausible docking region of the two molecules, which could be
further stabilized by neighboring beta strands contributed by both
CLR molecules. CLR has three putative N-glycosylation sites;
Asn66, Asn118 and Asn123; glycosylation of either Asn66 or
Asn118 seems essential for normal pharmacological functioning
[11]. On the model, all three sites on the CLR ECD-B are freely
accessible for post-translational modiﬁcations.
4. Discussion
The results of this investigation suggest a small number of
residues in the extreme N-terminus of CLR are important for
receptor function, in particular, Ile41, Ala44, Gln45, Cys48 and
Tyr49. Mutation of these residues either disrupts CGRP-stimulated
cAMP production, CGRP binding or CLR expression at the cell
surface. There is also some evidence for a second cluster of
important residues consisting of Ile32, Gly35 and Thr37.
Cys48 is predicted to take part in one of the highly conserved
disulﬁde bonds that characterize the ECDs of family B GPCRs and
its mutation to alanine in other receptors also causes a loss of
signaling [18]. The other residues, apart from Tyr49 are not widely
conserved and so must have receptor-speciﬁc roles.
The extreme N-terminus of the CLR is predicted to adopt an
alpha helical conformation between Asn39 and Gln54. Ile41, Gln45
and Tyr49 are predicted to lie on the same face of the extreme N-
terminus helix. Gln45A and Tyr49A appear to be expressed
normallywithin the cell but are not trafﬁcked to the cell surface. As
cell surface expression of CLR requires associationwith RAMPs, it is
possible that the mutations block this process. Our model suggests
that the CLR N-terminal helix of CLR-A is predicted to dock against
helix 3 of RAMP1. It has previously been suggested that Phe93,
His97 and Phe101 of RAMP1 participate in a CLR binding interface
[16,28]. The model predicts that a hydrogen bond occurs between
the side chain amide of Gln45 of CLR-A and the epsilon nitrogen of
His97 of RAMP1; the residues are appropriately orientated to allow
this interaction. Tyr49 of CLR-A and Phe93 of RAMP1 may pack
together.
Ile41 appears to be too far away from RAMP1 to make a
signiﬁcant hydrophobic interaction, consistent with its normal
cell surface expression. However, Ile41 impairs cAMP accumula-
tion and speciﬁc binding suggesting that it is involved directly in
CGRP binding. Therefore, the RAMP1/CLR-A interface may also
provide a platform for CGRP docking. This is further supported by
Ala44, which is predicted to face away from RAMP1, as Ala44Leu
selectively decreases CGRP responsivenesswith little effect on the
expression of the CGRP receptor. It is possible that Gln45 and
Tyr49 may also participate in CGRP binding, in addition to their
roles in interacting with RAMP1. In the presence of 50%
triﬂuoroethanol (TFE) CGRP has an 80% a helical content [27];
our model suggests that there is sufﬁcient space to accommodate
a linear peptide (corresponding to an extended form of CGRP) in
the groove between RAMP1 and the a helix of the A monomer of
CLR.
Ile32, Gly35 and Thr37 form a cluster of residues on the extreme
N-terminus of CLR that increase in CGRP potency. At this part of the
N-terminus, the accuracy of family B alignments decreases.
Accordingly, it is difﬁcult to use the model to make any useful
comments as to the mechanism for this effect, beyond noting that
they cluster at the base of the known helix. However, it suggests
that there are extended contact points for CGRP along the entire
region. Deletion of the ﬁrst 18 residues of this section (as far as
Lys40) gives a receptor that cannot respond to CGRP [15] and an
alanine scan of the same region found that the mutants Leu24Ala
and Leu34Ala decreased CGRP potency, but not binding [2]. Whilst
there is agreement with the current study that this part of the N-terminus has a role in CGRP binding, the residues identiﬁed are
different. There may be cell-line speciﬁc factors at work; as the
authors observed a decrease in binding but not in signaling, their
receptors may have been very efﬁciently coupled to Gs.
Lys51, which increased basal activity, faces away from RAMP1,
towards Asp96 on the second CLR of the dimer (Fig. 3). It is possible
that the mutation Lys51A disrupts the CLR dimer interface leading
to an alteration in the conformation of the N-terminus and so to
enhanced constitutive activity.
For a number of mutants, there was an increase in cell surface
expression. This generally correlates with an increase in total
expression. At present, it is difﬁcult to suggest any detailed
mechanism for this.
It has been proposed that family B GPCRs share a common fold
in their ECDs [23]. Consequently, the RAMP interface identiﬁed
here may also be shared amongst other family B GPCRs that have
been found to complex with the RAMP family [3]. It is clear that
there are at differences as to how different RAMPs interact with
CLR or other GPCRs. For example, residues 23–40 of CLR can be
replaced by the corresponding sequence of the porcine calcitonin
receptor and still form a functional CGRP receptor; the same
replacement is not enough to preserve the RAMP2 interaction and
adrenomedullin binding [15]. It is plausible that the overall
architecture of the GPCR–RAMP complex may be conserved for
these receptors, but the inﬂuence of different RAMPs may alter the
position of the extreme N-terminus to reveal or mask certain
binding epitopes.
In conclusion, this study has revealed a cluster of residues likely
to lie on a helix at the extreme N-terminus of CLR that are
important for RAMP association and the direct binding of CGRP.
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